Cargando…
Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new ‘revolutionary’ therapeutics?
Linked Article: Zamagni et al. Br J Dermatol 2022; 187:52–63.
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542168/ https://www.ncbi.nlm.nih.gov/pubmed/35415923 http://dx.doi.org/10.1111/bjd.21583 |
| _version_ | 1784804088777539584 |
|---|---|
| author | Harvima, Ilkka T. Harvima, Rauno J. |
| author_facet | Harvima, Ilkka T. Harvima, Rauno J. |
| author_sort | Harvima, Ilkka T. |
| collection | PubMed |
| description | Linked Article: Zamagni et al. Br J Dermatol 2022; 187:52–63. |
| format | Online Article Text |
| id | pubmed-9542168 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95421682022-10-14 Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new ‘revolutionary’ therapeutics? Harvima, Ilkka T. Harvima, Rauno J. Br J Dermatol Commentaries Linked Article: Zamagni et al. Br J Dermatol 2022; 187:52–63. John Wiley and Sons Inc. 2022-04-12 2022-07 /pmc/articles/PMC9542168/ /pubmed/35415923 http://dx.doi.org/10.1111/bjd.21583 Text en © 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Commentaries Harvima, Ilkka T. Harvima, Rauno J. Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new ‘revolutionary’ therapeutics? |
| title | Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new ‘revolutionary’ therapeutics? |
| title_full | Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new ‘revolutionary’ therapeutics? |
| title_fullStr | Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new ‘revolutionary’ therapeutics? |
| title_full_unstemmed | Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new ‘revolutionary’ therapeutics? |
| title_short | Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new ‘revolutionary’ therapeutics? |
| title_sort | survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new ‘revolutionary’ therapeutics? |
| topic | Commentaries |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542168/ https://www.ncbi.nlm.nih.gov/pubmed/35415923 http://dx.doi.org/10.1111/bjd.21583 |
| work_keys_str_mv | AT harvimailkkat survivalfromcutaneousmalignantmelanomaisimprovingbutisitbecauseofatrendindecreasingmelanomathicknessortheadventofnewrevolutionarytherapeutics AT harvimaraunoj survivalfromcutaneousmalignantmelanomaisimprovingbutisitbecauseofatrendindecreasingmelanomathicknessortheadventofnewrevolutionarytherapeutics |